VSports在线直播 - Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in VSports app下载. gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely V体育官网. .

. 2013 Apr 30;32(1):25.
doi: 10.1186/1756-9966-32-25.

VSports最新版本 - Tau protein as a potential predictive marker in epithelial ovarian cancer patients treated with paclitaxel/platinum first-line chemotherapy

Marta Smoter  1 , Lubomir Bodnar, Bartlomiej Grala, Rafal Stec, Krystyna Zieniuk, Wojciech Kozlowski, Cezary Szczylik
Affiliations

Tau protein as a potential predictive marker in epithelial ovarian cancer patients treated with paclitaxel/platinum first-line chemotherapy

Marta Smoter et al. J Exp Clin Cancer Res. .

Abstract

Background: The aim of the study was to evaluate predictive and prognostic significance of microtubule-associated protein Tau in epithelial ovarian cancer (EOC) patients treated with paclitaxel and platinum-based chemotherapy. VSports手机版.

Methods: 74 patients with EOC (stage I-IV) who underwent cytoreductive surgery followed by standard paclitaxel/platinum chemotherapy were included in the retrospective analysis. Their formalin-fixed, paraffin-embedded tissue specimens were immunohistochemically stained for Tau protein, using semi-quantitative DAKO test. Tau expression was acknowledged as negative (0 and 1+) or positive (2+ and 3+) V体育安卓版. The correlation between Tau expression, progression free survival (PFS) and overall survival (OS) was evaluated. Statistical analysis included Kaplan-Meyer estimator, long rank test, Mann Whitney test and Cox proportional hazards model. .

Results: 25. 7% (19/74) and 74 V体育ios版. 3% (55/74) of the patients were classified as Tau-negative and Tau-positive, respectively. Median PFS was 28. 7 months for Tau-negative group and 15. 9 months for Tau-positive group (p = 0. 0355). In the univariate analysis 3-year OS in Tau-negative and Tau-positive groups was 80. 2% and 52. 4%, respectively (p = 0. 0198). Low expression of protein Tau was associated with better OS, whereas an advanced stage at diagnosis, suboptimal surgery, serous histological type and resistance to first line chemotherapy were each correlated with worse OS (p <0,05). In multivariate analysis only resistance to first line chemotherapy remained significant (HR 22. 59; 95% CI, 8. 71-58. 55; p <0. 0001). .

Conclusions: Negative tau protein seems to be both good prognostic factor and a predictor of response to paclitaxel/platinum-based chemotherapy in EOC patients. VSports最新版本.

PubMed Disclaimer

"VSports在线直播" Figures

Figure 1
Figure 1
Tau protein expression by IHC (a-d). Tau 0 (a) - completely negative staining with anti-Tau antibody in tumor cells (left). Moderately intense staining of fallopian tube epithelium on the right (double arrows) serves as internal positive control (magnification 200×). Tau 1+ (b) Adenocarcinoma cells with weak focal expression of Tau protein (magnification 200×). Tau 2+ (c) Moderately intense staining of tumor cells similar to pattern of staining of superficial ovarian epithelium (arrow) (magnification 200×). Tau 3+ (d) Intense and diffuse staining as dark cytoplasmatic granules.
Figure 2
Figure 2
Progression free survival by tau expression.
Figure 3
Figure 3
Overall survival by tau expression.
See this image and copyright information in PMC

References

    1. McGuire WP, Hoskins WJ, Brady MF. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1–6. doi: 10.1056/NEJM199601043340101. - DOI - PubMed
    1. Piccart M, Bertrlsen K, James K. Randomized intergroup trial of cisplatin- paclitaxel versus cisplatin- cyclophosphamide in women with advanced epithelial ovarian cancer: three year results. J Natl Cancer Inst. 2000;92:699–708. doi: 10.1093/jnci/92.9.699. - DOI (VSports app下载) - PubMed
    1. Amos LA, Löwe J. How Taxol stabilises microtubule structure. Chem Biol. 1999;6:65–9. doi: 10.1016/S1074-5521(99)89002-4. - DOI - PubMed
    1. Rouzier R, Rajan R, Wagner P. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci USA. 2005;102:8315–20. doi: 10.1073/pnas.0408974102. - DOI - PMC - PubMed
    1. Kar S, Fan J, Smith MJ, Goedert M, Amos LA. Repeat motifs of tau bind to the insides of microtubules in the absence of taxol. EMBO J. 2003;22:70–77. doi: 10.1093/emboj/cdg001. - DOI - PMC - PubMed

Publication types

MeSH terms